Mevigut SR Capsule (Sustained Release) 200 mg Uses, Dosage, Side Effects and more

Mevigut SR Capsule (Sustained Release) 200 mg Uses, Dosage, Side Effects, Food Interaction and all others data.

Table Of contents

• Mevigut SR Capsule (Sustained Release) 200 mg
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	Mevigut SR Capsule (Sustained Release) 200 mg
Generic	Mebeverine Hydrochloride
Weight	200 mg
Type	Capsule (Sustained Release)
Therapeutic Class	Anticholinergics
Manufacturer	NIPRO JMI Pharma Ltd.
Available Country	Bangladesh
Last Updated:	January 7, 2025 at 1:49 am

Uses

Mebeverine is indicated for the: Symptomatic treatment of irritable bowel syndrome (IBS) Chronic irritable colon Spastic constipation Mucous colitis Colicky abdominal pain Persistent non-specific diarrhoea

Dosage

Mevigut SR Capsule (Sustained Release) 200 mg dosage

For adults, elderly and children over 10 years: Mevigut SR Capsule (Sustained Release) 200 mg 135 mg tablet: 1 tablet 03 times daily. Mevigut SR Capsule (Sustained Release) 200 mg 200 mg capsule: 1 capsule 02 times daily. This is most effective when taken 20 minutes before meals. After several weeks when the desired effect has been obtained, the dosage may be gradually reduced.Missed dose: If a dose of this medicine is missed, that should be taken as soon as possible. However, if it is almost time for the next dose, then skip the missed dose and the regular dosing schedule should be maintained. Dose should not be doubled at the same time to compensate the missed dose.Use in children: Mebeverine is not recommended for children under 10 years.

Side Effects

Generally Mebeverine is well tolerated. However, few side-effects like skin rash, urticaria and angioedema may appear

Precaution

Caution should be exercised in porphyria or allergic reaction to this or any other medicine of this group.

Pregnancy & Breastfeeding use

No teratogenicity has been shown in animal experiments. However, the usual precautions concerning the administration of any drug during pregnancy should be exercised. Mebeverine does not excrete in the breast milk after administering at therapeutic dose.

Contraindication

Hypersensitivity to the drug or any other ingredients.

Acute Overdose

On theoretical grounds it may be predicted that CNS excitability will occur in case of overdosage. No specific antidote is known: gastric lavage and symptomatic treatment is recommended

Storage Condition

Do not store above 30°C. Keep away from light and out of the reach of children.

Innovators Monograph